Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.
about
Non-canonical signaling mode of the epidermal growth factor receptor familyTargeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptidesBCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenibEffect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell LinesIdentification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission TomographyInduction of P-glycoprotein and Bcrp at the rat blood-brain barrier following a subchronic morphine treatment is mediated through NMDA/COX-2 activationRegulation of voltage-gated potassium channels attenuates resistance of side-population cells to gefitinib in the human lung cancer cell line NCI-H460β-adrenergic receptor-dependent alterations in murine cardiac transcript expression are differentially regulated by gefitinib in vivoARRY-334543 reverses multidrug resistance by antagonizing the activity of ATP-binding cassette subfamily G member 2.EGFR modulates DNA synthesis and repair through Tyr phosphorylation of histone H4.ADAM9 up-regulates N-cadherin via miR-218 suppression in lung adenocarcinoma cellsABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors.Photochemical internalisation, a minimally invasive strategy for light-controlled endosomal escape of cancer stem cell-targeting therapeutics.Suppression of human breast tumors in NOD/SCID mice by CD44 shRNA gene therapy combined with doxorubicin treatmentNuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor familyLapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6.Targeting MDR in breast and lung cancer: discriminating its potential importance from the failure of drug resistance reversal studies.Syntaxin 6-mediated Golgi translocation plays an important role in nuclear functions of EGFR through microtubule-dependent trafficking.Transcription factors Sp1 and Sp3 regulate expression of human ABCG2 gene and chemoresistance phenotypeOral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.The ins and outs of fibroblast growth factor receptor signalling.Masitinib antagonizes ATP-binding cassette subfamily G member 2-mediated multidrug resistance.The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer.Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer.Prognostic significance of NSE mRNA in advanced NSCLC treated with gefitinib.Effects of Concomitant Medication Use on Gefitinib-Induced Hepatotoxicity.Expression and subcellular localization of efflux transporter ABCG2/BCRP in important tissue barriers of lactating dairy cows, sheep and goats
P2860
Q26773754-42362245-70F1-4AFC-9DAD-001DF59D164BQ28486075-832C5294-67DD-446A-B499-7D925806B02DQ28538126-A6807FE6-8771-41A9-AAA2-8267FAE3702DQ28550693-EF061A51-154C-417C-B1F9-A265AD9CA81EQ28553692-59CE26F6-51CF-4E5F-9C46-CE8A844FEE26Q28578377-A73037FD-18AC-40F9-80F1-7D995C74E9CBQ32181933-5AAED6AD-F284-4CEA-BAE6-814053E3ADFDQ33717215-81AD9A96-290C-441D-9402-C1EDBD282DFEQ33861296-F57D7579-8924-45BA-815B-CBA56C850B69Q34109344-323F5916-8F57-402C-8408-EADF66FBB3DCQ35140315-7CEEDCF7-ACEF-4E37-8532-8CDD51EA9D22Q35171274-266BDC51-2E59-413C-BC87-AFE292D9A596Q35585820-A33BCCEB-23C7-4AC2-92FA-2A6EAADE34F3Q35979751-670DABC5-AFD0-410E-8CCA-0EA0008F1B60Q36162605-14B746AA-B613-422F-9E5F-4F24D1F1F4D0Q36545926-D84E64C0-84F6-4B3F-AFF1-EE9EF2B34A34Q36923104-2647CFE0-28A1-4696-8990-4D30ED403025Q37417599-2CD76BCB-E30F-47B8-8E75-0E1FAF5BE605Q37462746-A1341CF3-E79A-4AC0-B3B3-48E51A1FB3EFQ38082728-346C24B8-4448-4EE6-8C7C-7AAECF8318DAQ38208062-3ECF2AF3-EAE2-42F4-85D7-AEFDB19293BCQ39015818-0267D5E7-02B3-4156-9EE8-F2E3C2525CB5Q39028181-91CB5EBE-AFD1-43DB-94A0-91C06B37012AQ39412894-06145F15-DA37-4E3B-917A-B043F8F9F682Q43515674-DE9B235F-4087-4766-AC06-3B16204397FAQ45720480-E2278319-6563-46F3-AFDB-83536B806CCDQ49582579-DCFD55D8-FE72-4381-B7B1-41FD1D5FE5A6Q57155163-9F59F1B0-BB6B-4B09-913E-59ED3E67EC83
P2860
Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Elevated BCRP/ABCG2 expression ...... ld-type EGFR-expressing cells.
@ast
Elevated BCRP/ABCG2 expression ...... ld-type EGFR-expressing cells.
@en
type
label
Elevated BCRP/ABCG2 expression ...... ld-type EGFR-expressing cells.
@ast
Elevated BCRP/ABCG2 expression ...... ld-type EGFR-expressing cells.
@en
prefLabel
Elevated BCRP/ABCG2 expression ...... ld-type EGFR-expressing cells.
@ast
Elevated BCRP/ABCG2 expression ...... ld-type EGFR-expressing cells.
@en
P2093
P2860
P1433
P1476
Elevated BCRP/ABCG2 expression ...... ld-type EGFR-expressing cells.
@en
P2093
Chang-Hai Tsai
Chao-Kai Chou
Chia-Jui Yen
Heather Y Lin
J Jack Lee
Kwang-Yu Chang
Mien-Chie Hung
Sheng-Chieh Hsu
Tse-Chuan Chou
P2860
P304
P356
10.1371/JOURNAL.PONE.0021428
P407
P577
2011-06-23T00:00:00Z